Bayer faces scrutiny over drug progress and earnings outlook

Bayer investors are currently weighing pharmaceutical innovation against the need for concrete financial results. While UBS recently issued a buy recommendation following progress in drug development, analysts have lowered expectations for the third quarter.

A key development involves the drug Finerenon. The FDA recently accepted a supplemental application to treat adults with chronic kidney disease without diabetes, based on positive Phase III FIND-CKD study results. However, the acceptance of the application does not constitute final approval for this patient group.

Investors are looking toward the company's quarterly report scheduled for November 3 to determine if these research advancements can translate into a convincing economic perspective and improved earnings.